Salmonella Testing Market By Testing Method (Culture-Based Testing, Molecular Testing [PCR & LAMP], Immunoassays, Other Rapid Testing Methods); By Sample Type (Food & Beverage, Clinical Samples, Animal Feed & Veterinary Samples, Environmental & Water Samples); By Food Type (Meat & Poultry, Dairy Products, Eggs & Egg Products, Fruits & Vegetables, Processed & Packaged Foods, Other Foods); By End User (Food & Beverage Manufacturers, Diagnostic & Clinical Laboratories, Government & Public Health Laboratories, Contract Testing Laboratories, Veterinary & Animal Health Laboratories); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Salmonella Testing Market: Expanding Food Safety Surveillance Driven by Molecular Diagnostics, Outbreak Investigations, and Global Regulatory Compliance

The Global Salmonella Testing Market was valued at USD 3.34 billion in 2025 and is projected to reach USD 5.29 billion by 2032, expanding at a CAGR of 6.8% during 2026–2032.

 

Salmonella testing refers to laboratory methods used to detect the presence of Salmonella bacteria in different types of samples, such as human clinical specimens, food products, animals, animal feed, and environmental surfaces. In healthcare, it is commonly done using stool samples to diagnose intestinal infections, and sometimes blood tests are used when the infection is more severe or has spread in the body. In the food industry, testing is carried out by manufacturers, laboratories, and regulatory authorities to ensure products are safe before they reach consumers and to trace the source if contamination is found.

 

The FDA-approved standard for detecting Salmonella in food is outlined in the Bacteriological Analytical Manual (BAM) Chapter 5, which uses a stepwise culture process where samples are first enriched in nutrient broth to revive bacteria, then transferred to selective media to encourage Salmonella growth, followed by plating to isolate colonies and confirmatory biochemical and serological testing for final identification. Alongside this reference method, the FDA also accepts validated rapid alternatives, including AOAC-approved PCR tests that detect Salmonella DNA and immunoassay or lateral flow tests that provide quick screening results; these are increasingly used for faster decision-making in food safety, while culture-based BAM testing remains the required standard for regulatory confirmation.

 

How large is the Salmonella testing demand in public health systems?

The demand for Salmonella testing in public health systems is driven by a high and persistent disease burden, which translates into continuous diagnostic, surveillance, and outbreak investigation activity. CDC estimates approximately 1.35 million Salmonella infections annually in the United States, making it one of the most frequently tested bacterial pathogens in clinical and foodborne disease surveillance.

Updated burden estimates further show that nontyphoidal Salmonella accounts for about 1.28 million illnesses, 12,500 hospitalizations, and 238 deaths each year, reinforcing the scale of routine diagnostic testing required across hospitals, reference laboratories, and public health agencies.

FoodNet surveillance highlights the operational testing load, reporting 9,219 confirmed infections in 2024, including 2,769 hospitalizations and 63 deaths. These cases typically trigger multiple layers of laboratory work, including initial clinical testing, confirmatory culture, serotyping, antimicrobial resistance profiling, and in outbreak situations, genomic sequencing.

Testing demand is also being reshaped by diagnostic technology shifts. In 2024, 78% of bacterial infections in FoodNet were diagnosed using culture-independent diagnostic tests (CIDTs), compared with 47% in 2016–2018. This has increased the use of rapid molecular panels for initial detection while maintaining the need for culture-based confirmation in public health workflows. CDC data also shows that reported Salmonella incidence has increased over time alongside broader adoption of molecular diagnostics, reinforcing sustained growth in both rapid testing and confirmatory laboratory demand.

 

Why are molecular and multiplex tests gaining commercial importance?

Traditional culture remains important, but molecular testing is increasingly reshaping Salmonella diagnostics and testing workflows. CDC notes that culture-independent diagnostic tests (CIDTs) can deliver faster results and detect Salmonella DNA or antigens without requiring organism growth. However, a positive molecular result may not always yield an isolate needed for serotyping, antimicrobial susceptibility testing, or outbreak comparison. As a result, CDC recommends reflex culture when Salmonella is detected through multiplex PCR panels or other CIDTs.

This creates a hybrid testing model rather than a full replacement of culture. Hospitals and reference laboratories increasingly rely on molecular assays for rapid detection, while public-health laboratories continue to depend on culture for confirmation, serotyping, resistance profiling, and genomic sequencing. Food-testing laboratories follow a similar approach, using PCR or LAMP methods for rapid screening and reserving culture-based methods for confirmation and regulatory compliance.

Commercially, this shift is driving demand for faster molecular platforms alongside sustained demand for culture consumables and confirmatory workflows. FDA has also incorporated real-time PCR and LAMP methods into validated Salmonella food-testing protocols, reinforcing their role in routine testing.

At the same time, product development is moving toward more targeted and efficient testing panels. Instead of broad gastrointestinal panels, manufacturers are introducing smaller, more focused assays that include Salmonella as a key target. For example, QIAGEN’s Mini B&V panel includes Salmonella among five pathogens, while bioMérieux’s BIOFIRE GI Panel Mid offers a reduced 11-target format compared to its broader 22-target panel. These developments support faster, more cost-efficient testing in both clinical and food-testing environments.

 

How is the Salmonella Testing Market structured across key dimensions?

Evolving Diagnostic Modalities Reshaping Salmonella Testing Demand

Culture-Based Testing accounted for the largest share of the market in 2025 at 38.0%, equivalent to USD 1.269 billion, and is projected to expand at a 4.7% CAGR. Its leading position reflects continued use in regulatory confirmation, isolate recovery, serotyping, antimicrobial susceptibility testing, and outbreak investigation. Although its growth is slower than newer technologies, culture remains difficult to replace where viable isolates are required for public-health and regulatory decisions.

Molecular Testing [PCR & LAMP] represented 33.0% of the market, valued at USD 1.102 billion in 2025, and is expected to record the fastest growth among the major testing methods at a 9.0% CAGR. Demand is being supported by laboratories and food companies seeking shorter turnaround times and more rapid contamination decisions. Wider adoption of multiplex clinical panels and validated molecular food-testing assays is shifting a larger portion of testing expenditure toward PCR- and LAMP-based platforms.

Immunoassays held a 21.0% share, or USD 0.701 billion, in 2025 and are projected to grow at a 6.3% CAGR. Their commercial position is supported by relatively straightforward screening workflows and use in laboratories and food-testing operations where rapid preliminary results are valuable before further confirmation.

Other Rapid Testing Methods accounted for 8.0% of the market, valued at USD 0.267 billion, and are forecast to expand at a 7.5% CAGR. Growth in this segment is linked to demand for quicker screening options in food-processing environments, contract laboratories, and decentralized testing settings where faster release or investigation decisions can reduce operational delays.

 

Sample-Matrix Segmentation Driving Diagnostic and Food-Safety Testing Demand

Food & Beverage samples represented the largest segment in 2025 with a 57.0% market share and USD 1.904 billion in value, while the segment is projected to grow at a 7.0% CAGR. Its dominance reflects routine testing across food manufacturing, regulatory surveillance, environmental monitoring within production facilities, and investigations following contamination or outbreak signals. The scale of meat, poultry, egg, dairy, produce, and processed-food testing keeps food-related samples at the center of commercial demand.

Clinical Samples accounted for 21.0% of the market, valued at USD 0.701 billion, and are expected to expand at a 5.9% CAGR. Demand comes from hospitals, diagnostic laboratories, outpatient care, and public-health investigations, with molecular gastrointestinal panels increasing the speed and breadth of pathogen detection while culture continues to support confirmation and isolate recovery.

Animal Feed & Veterinary Samples held a 13.0% share, equivalent to USD 0.434 billion in 2025, and are forecast to grow at a 6.6% CAGR. Testing demand is linked to efforts to control Salmonella earlier in the food chain, particularly across poultry, livestock, animal-feed production, and veterinary surveillance programs.

Environmental & Water Samples represented 9.0% of the market, or USD 0.301 billion, and are projected to post a 7.3% CAGR. This segment is benefiting from greater emphasis on environmental monitoring within food facilities, source investigations, sanitation verification, and water-quality surveillance, particularly when contamination needs to be traced beyond the finished product.

 

Key Food Segments Driving Salmonella Testing Demand at Scale

Meat & Poultry remained the largest food-testing category, accounting for 35.0% of the overall market and USD 1.169 billion in 2025, with a projected 6.7% CAGR. High testing volumes are supported by regulatory verification programs, processor quality controls, and the continuing association of poultry and meat products with Salmonella surveillance and recalls.

Dairy Products represented 17.0% of the market, valued at USD 0.568 billion, and are forecast to grow at a 6.1% CAGR. Testing remains important across raw materials, finished dairy products, processing environments, and quality-control programs where contamination can affect large production batches.

Eggs & Egg Products accounted for a 13.0% share, equivalent to USD 0.434 billion, and are projected to expand at a 5.8% CAGR. The segment remains commercially important because Salmonella Enteritidis continues to be closely monitored in egg supply chains, and recent European outbreaks have reinforced the need for testing and traceability.

Fruits & Vegetables held 14.0% of the market, valued at USD 0.468 billion in 2025, and are expected to record the fastest growth among major food categories at an 8.1% CAGR. Increasing surveillance of fresh and minimally processed produce, along with concern over contamination from irrigation water, handling, packing, and processing environments, is increasing testing requirements.

Processed & Packaged Foods represented 16.0% of the market, or USD 0.534 billion, and are projected to grow at a 7.5% CAGR. Growth reflects broader ingredient sourcing, complex supply chains, and the financial impact of recalls, encouraging manufacturers to use routine pathogen testing before product release.

Other Foods accounted for the remaining 5.0% share, valued at USD 0.167 billion, and are forecast to expand at a 6.2% CAGR. This category includes a range of specialty and lower-volume food matrices where testing requirements vary according to product risk, sourcing, and regulatory expectations.

 

Salmonella Testing Demand Concentration Across High-Impact End-Use Sectors

Food & Beverage Manufacturers were the largest end-user group in 2025, representing 41.0% of the market and USD 1.369 billion, with demand projected to grow at a 7.0% CAGR. Manufacturers account for a substantial portion of routine testing because contamination can lead to product holds, recalls, destroyed inventory, production disruption, and reputational damage. Testing is therefore integrated into quality-control and food-safety programs throughout manufacturing operations.

Diagnostic & Clinical Laboratories accounted for 20.0% of the market, valued at USD 0.668 billion, and are expected to grow at a 6.2% CAGR. Their demand is supported by clinical diagnosis, multiplex gastrointestinal testing, hospital testing volumes, and confirmatory workflows associated with reportable infections.

Government & Public Health Laboratories held a 14.0% share, or USD 0.468 billion, and are projected to expand at a 5.7% CAGR. These laboratories remain central to outbreak confirmation, surveillance, serotyping, antimicrobial-resistance monitoring, and whole-genome sequencing, even as routine screening increasingly moves toward rapid molecular approaches.

Contract Testing Laboratories represented 17.0% of the market, valued at USD 0.568 billion in 2025, and are forecast to record the fastest end-user growth at an 8.0% CAGR. Food manufacturers increasingly use external laboratories for validated pathogen testing, specialized assays, overflow capacity, and independent verification, supporting higher testing volumes for commercial laboratory service providers.

Veterinary & Animal Health Laboratories accounted for 8.0% of the market, equivalent to USD 0.267 billion, and are projected to grow at a 6.5% CAGR. Their role is linked to surveillance across livestock, poultry, animal feed, breeding environments, and veterinary investigations designed to reduce Salmonella transmission before it reaches the human food chain.

 

How are leading companies competing in the Salmonella testing market?

bioMérieux has exposure to both clinical and food-industry Salmonella testing. Its BIOFIRE gastrointestinal portfolio includes the 22-target GI Panel and the 11-target GI Panel Mid, both containing Salmonella. On the food side, the company markets GENE-UP Salmonella molecular testing and expanded its portfolio in June 2026 with GENE-UP TYPER SLM, a real-time PCR-based assay designed to discriminate Salmonella enterica strains for contamination source investigation. This positions bioMérieux across initial detection, syndromic diagnosis, and food-industry source tracking.

QIAGEN is competing through its QIAstat-Dx syndromic platform. FDA clearance of the Gastrointestinal Panel 2 Mini B&V in January 2025 added a targeted five-pathogen option containing Salmonella, and another bacterial-only mini panel received U.S. clearance in March 2025. The portfolio allows QIAGEN to address both broader hospital GI testing and more targeted outpatient testing.

Neogen has a stronger position in food and regulatory laboratory testing. In April 2024 it launched a molecular assay specifically targeting Salmonella Enteritidis and Salmonella Typhimurium. In June 2024, USDA FSIS selected Neogen's Molecular Detection System as its primary method under a new contract for Salmonella and Listeria monocytogenes testing of meat, poultry, and egg products. That government use provides an important competitive reference for food-testing customers.

Thermo Fisher Scientific competes through the SureTect real-time PCR portfolio. Its Salmonella assays cover general Salmonella species testing as well as multiplex detection of Salmonella species, Typhimurium, and Enteritidis, with validation claims including ISO 16140-2 and AOAC pathways for relevant products and matrices. Its strategy is closely aligned with food manufacturers and laboratories that already operate real-time PCR infrastructure.

Hygiena addresses food-production and contract-laboratory customers through the BAX System and foodproof PCR portfolio. The BAX Q7 platform supports Salmonella, Listeria, and E. coli testing, while SalQuant extends the portfolio into quantitative Salmonella analysis for poultry, beef, and pork. This moves competition beyond simple presence/absence testing toward information that processors can use to measure contamination levels and assess process control.

 

What regional factors are shaping the growth of Salmonella testing across global markets?

North America has one of the most developed combinations of clinical, public-health, regulatory, and commercial food-testing demand, accounting for a 35.0% market share valued at USD 1.169 billion in 2025 and growing at a CAGR of 6.0%. U.S. FoodNet reported 9,219 Salmonella infections in its 2024 surveillance dataset, while FDA and USDA maintain established laboratory and verification programs. Canada adds recurring food-industry testing through CFIA's Pathogen Reduction Monitoring Program for Salmonella and Campylobacter in raw poultry.

Europe combines a high reported disease burden with formal microbiological criteria and extensive cross-border surveillance. The EU recorded 79,703 salmonellosis cases in 2024, while only 14 Member States met all established Salmonella-reduction targets for relevant poultry populations, down from 19 in 2022. Current multi-country investigations and mandatory WGS requirements for outbreak-associated isolates support demand for molecular detection, confirmation, typing, and genomic surveillance. Europe accounted for a 29.0% market share, valued at USD 0.969 billion, and is projected to grow at a CAGR of 6.4%.

Asia-Pacific represents a diverse testing environment ranging from mature national surveillance systems to countries still strengthening laboratory capacity, and it accounted for 24.0% of the market, valued at USD 0.802 billion, with a projected CAGR of 8.4%. Australia maintains Salmonella as a nationally notifiable disease and publishes NNDSS data by year, state, age, sex, and serovar; its public dataset currently provides detailed records through 2024. Wider regional demand is also supported by food exports, international supply chains, and continued investment in laboratory-based foodborne-disease surveillance.

Latin America is developing stronger genomic surveillance capacity. PAHO's 2024 PulseNet Latin America and Caribbean meeting included public-health specialists from 18 countries and focused on genomic tools for pathogens including Salmonella, Campylobacter, and Vibrio cholerae. PAHO's ReLAVRA+ network has also historically included Salmonella among targeted foodborne pathogens for antimicrobial-resistance surveillance. These networks expand the need for standardized laboratory detection and isolate characterization rather than standalone local testing. Latin America accounted for 7.0% of the market, valued at USD 0.234 billion, and is projected to grow at a CAGR of 6.9%, supported by expanding surveillance programs and strengthening laboratory infrastructure.

Middle East and Africa have a different commercial profile, with growth tied more strongly to expansion of laboratory surveillance, food-safety infrastructure, reference laboratories, and enteric-fever testing capacity. The region accounted for a 5.0% market share, valued at USD 0.167 billion, and is projected to grow at a 6.7% CAGR. WHO released updated foodborne-disease surveillance manuals in late 2025 and emphasized laboratory-based surveillance, rapid risk assessment, outbreak response, and integration of public-health, food-safety, animal-health, and environmental data. This points to longer-term demand for affordable molecular platforms, culture consumables, reference testing, and sequencing capacity where surveillance systems are being strengthened.

 

What will shape future commercial opportunities in Salmonella testing?

The main opportunity in Salmonella testing is the move toward a detect–confirm–characterize–investigate workflow. Rapid molecular tests are widely used for quick screening, but culture methods remain essential for confirmation and isolate recovery. Whole-genome sequencing (WGS) is increasingly used in outbreak tracking, so both rapid and traditional methods are used together rather than replacing each other. CDC also recommends reflex culture after positive molecular (CIDT) results, reinforcing this combined approach.

Food manufacturers are also demanding more advanced and actionable testing. A positive result can lead to product holds, recalls, and trace-back investigations. In response, companies are adding more specialized tools—for example, bioMérieux launched GENE-UP TYPER SLM in 2026 for Salmonella strain identification, while Hygiena’s SalQuant enables quantitative Salmonella measurement in food products.

However, faster testing does not remove the need for confirmation. CIDTs improve speed and detection but still require follow-up culture for regulatory approval, antimicrobial testing, and sequencing. As a result, the strongest market position is held by companies offering both rapid screening and confirmatory or characterization solutions, rather than speed alone.

 

Salmonella Testing Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.34 Billion
Revenue Forecast in 2032	USD 5.29 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Testing Method, By Sample Type, By Food Type, By End User, By Geography
By Testing Method	Culture-Based Testing, Molecular Testing [PCR & LAMP], Immunoassays, Other Rapid Testing Methods
By Sample Type	Food & Beverage, Clinical Samples, Animal Feed & Veterinary Samples, Environmental & Water Samples
By Food Type	Meat & Poultry, Dairy Products, Eggs & Egg Products, Fruits & Vegetables, Processed & Packaged Foods, Other Foods
By End User	Food & Beverage Manufacturers, Diagnostic & Clinical Laboratories, Government & Public Health Laboratories, Contract Testing Laboratories, Veterinary & Animal Health Laboratories
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Molecular and multiplex testing adoption, persistent foodborne Salmonella surveillance and outbreak investigations, stricter food-safety and regulatory compliance requirements, growing use of genomic sequencing and environmental monitoring
Customization Option	Available upon request